Abstract Phosphodiesterase 4 (PDE4) belongs to a family of enzymes which catalyzes the
breakdown of 3, 5′-adenosine cyclic monophosphate (cAMP) and is ubiquitously
expressed in inflammatory cells. There is little evidence that inflammatory diseases are
caused by increased expression of this isoenzyme, although human inflammatory cell
activity can be suppressed by selective PDE4 inhibitors. Consequently, there is intense
interest in the development of selective PDE4 inhibitors for the treatment of a range of …

Study design: Open, before–after study. Objective: To assess the efficacy and safety of
phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction (ED) in spinal cord-
injured (SCI) patients. Setting: Home-and clinic-based assessments in the outpatient
department at the Centre Bouffard Vercelli, Cerbère France. Methods: Clinic trials with
Sildenafil (Viagra®) on 120 patients, Tadalafil (Cialis®) on 54 patients and Vardenafil
(Levitra®) on 66 patients were performed. Flexible doses of PDE5 inhibitors were given …